Health
Who Should Be Allowed a Medically Assisted Death?
Ron Curtis, an English professor in Montreal, lived for 40 years with a degenerative spinal disease, in what he called the “black hole” of chronic pain.
On a July day in 2022, Mr. Curtis, 64, ate a last bowl of vegetable soup made by his wife, Lori, and, with the help of a palliative care doctor, died in his bedroom overlooking a lake.
Aron Wade, a successful 54-year-old stage and television actor in Belgium, decided he could no longer tolerate life with the depression that haunted him for three decades.
Last year, after a panel of medical experts found he had “unbearable mental suffering,” a doctor came to his home and gave him medicine to stop his heart, with his partner and two best friends at his side.
Argemiro Ariza was in his early 80s when he began to lose function in his limbs, no longer able to care for his wife, who had dementia, in their home in Bogotá.
Doctors diagnosed A.L.S., and he told his daughter Olga that he wanted to die while he still had dignity. His children threw him a party with a mariachi band and lifted him from his wheelchair to dance. A few days later, he admitted himself to a hospital, and a doctor administered a drug that ended his life.
Until recently, each of these deaths would have been considered a murder. But a monumental change is underway around the world. From liberal European countries to conservative Latin American ones, a new way of thinking about death is starting to take hold.
Over the past five years, the practice of allowing a physician to help severely ill patients end their lives with medication has been legalized in nine countries on three continents. Courts or legislatures, or both, are considering legalization in a half-dozen more, including South Korea and South Africa, as well as eight of the 31 American states where it remains prohibited.
It is a last frontier in the expansion of individual autonomy. More people are seeking to define the terms of their deaths in the same way they have other aspects of their lives, such as marriage and childbearing. This is true even in Latin America, where conservative institutions such as the Roman Catholic church are still powerful.
“We believe in the priority of our control over our bodies, and as a heterogeneous culture, we believe in choices: If your choice does not affect me, go ahead,” said Dr. Julieta Moreno Molina, a bioethicist who has advised Colombia’s Ministry of Health on its assisted dying regulations.
Yet, as assisted death gains more acceptance, there are major unresolved questions about who should be eligible. While most countries begin with assisted death for terminal illness, which has the most public support, this is often followed quickly by a push for wider access. With that push comes often bitter public debate.
Should someone with intractable depression be allowed an assisted death?
European countries and Colombia all permit people with irremediable suffering from conditions such as depression or schizophrenia to seek an assisted death. But in Canada, the issue has become contentious. Assisted death for people who do not have a reasonably foreseeable natural death was legalized in 2021, but the government has repeatedly excluded people with mental illness. Two of them are challenging the exclusion in court on the grounds that it violates their constitutional rights.
In public debate, supporters of the right to assisted death for these patients say that people who have lived with severe depression for years, and have tried a variety of therapies and medications, should be allowed to decide when they are no longer willing to keep pursuing treatments. Opponents, concerned that mental illness can involve a pathological wish to die, say it can be difficult to predict the potential effectiveness of treatments. And, they argue, people who struggle to get help from an overburdened public health service may simply give up and choose to die, though their conditions might have been improved.
Should a child with an incurable condition be able to choose assisted death?
The ability to consent is a core consideration in requesting assisted death. Only a handful of countries are willing to extend that right to minors. Even in the places that do, there are just a few assisted deaths for children each year, almost always children with cancer.
In Colombia and the Netherlands, children over 12 can request assisted death on their own. Parents can provide consent for children 11 and younger.
Denise de Ruijter took comfort in her Barbie dolls when she struggled to connect with people. She was diagnosed with autism and had episodes of depression and psychosis. As a teenager in a Dutch town, she craved the life her schoolmates had — nights out, boyfriends — but couldn’t manage it.
She attempted suicide several times before applying for an assisted death at 18. Evaluators required her to try three years of additional therapies before agreeing her suffering was unbearable. She died in 2021, with her family and Barbies nearby.
The issue is under renewed scrutiny in the Netherlands, where, over the past decade, a growing number of adolescents have applied for assisted death for relief from irremediable psychiatric suffering from conditions such as eating disorders and anxiety.
Most such applications by teens are either withdrawn by the patient, or rejected by assessors, but public concern over a few high-profile cases of teens who received assisted deaths prompted the country’s regulator to consider a moratorium on approvals for children applying on the basis of psychiatric suffering.
Should someone with dementia be allowed assisted death?
Many people dread the idea of losing their cognitive abilities and their autonomy, and hope to have an assisted death when they reach that point. But this is a more complex situation to regulate than for a person who can still make a clear request.
How can a person who is losing their mental capacity consent to dying? Most governments, and doctors, are too uncomfortable to permit it, even though the idea tends to be popular in countries with aging populations.
In Colombia, Spain, Ecuador and the Canadian province of Quebec, people who have been diagnosed with Alzheimer’s disease or other kinds of cognitive decline can request assessment for an assisted death before they lose mental capacity, sign an advance request — and then have a physician end their life after they have lost the ability to consent themselves.
But that raises a separate, challenging, question: After people lose the capacity to request an assisted death, who should decide it’s time?
Their spouses? Their children? Their doctors? The government? Colombia entrusts families with this role. The Netherlands leaves it up to doctors — but many refuse to do it, unwilling to administer lethal drugs to a patient who can’t clearly articulate a rational wish to die.
Jan Grijpma was always clear with his daughter, Maria: When his mind went, he didn’t want to live any more. Maria worked with his longtime family doctor, in Amsterdam, to identify the point when Mr. Grijpma, 90 and living in a nursing home, was losing his ability to consent himself.
When it seemed close, in 2023, they booked the day, and he updated his day planner: Thursday, visit the vicar; Friday, bicycle with physiotherapy and get a haircut; Sunday, pancakes with Maria; Monday, euthanasia.
All of these questions are becoming part of the discussion as the right to control and plan one’s own death is pushed in front of reluctant legislatures and uneasy medical professionals.
Dr. Madeline Li, a Toronto psychiatrist, was given the task of developing the assisted-dying practice in one of Canada’s largest hospitals when the procedure was first decriminalized in 2015. She began with assessing patients for eligibility and then moved to providing medical assistance in dying, or MAID, as it is called in Canada. For some patients with terminal cancer, it felt like the best form of care she could offer, she said.
But then Canada’s eligibility criteria expanded, and Dr. Li found herself confronting a different kind of patient.
“To provide assisted dying to somebody dying of a condition who is not happy with how they’re going to die, I’m willing to assist them, and hasten that death,” she said. “I struggle more with people who aren’t dying and want MAID — I think then you’re assisting suicide. If you’re not dying — if I didn’t give you MAID, you wouldn’t otherwise die — then you’re a person who’s not unhappy with how you’re going to die. You’re unhappy with how you’re living.”
Who has broken the taboo?
For decades, Switzerland was the only country to permit assisted death; assisted suicide was legalized there in 1942. It took a further half century for a few more countries to loosen their laws. Now decriminalization of some form of assisted death has occurred across Europe.
But there has recently been a wave of legalization in Latin America, where Colombia was long an outlier, having allowed legal assisted dying since 2015.
Paola Roldán Espinosa had a thriving career in business in Ecuador, and a toddler, when she was diagnosed with A.L.S. in 2023. Her health soon deteriorated to the point that she needed a ventilator.
She wanted to die on her terms — and took the case to the country’s highest court. In February 2024, the court responded to her petition by decriminalizing assisted dying. Ms. Roldán, then 42, had the death she sought, with her family around her, a month later.
Ecuador has decriminalized assisted dying through constitutional court cases, and Peru’s Supreme Court has permitted individual exceptions to the law which prohibits the procedure, opening the door to expansion. Cuba’s national assembly legalized assisted dying in 2023, although no regulations on how the procedure will work are yet in place. In October, Uruguay’s parliament passed a long-debated law allowing assisted death for the terminally ill.
The first country in Asia to take steps toward legalization is South Korea, where a bill to decriminalize assisted death has been proposed at the National Assembly several times but has not come to a vote. At the same time, the Constitutional Court, which for years refused to hear cases on the subject, has agreed to adjudicate a petition from a disabled man with severe and chronic pain who seeks an assisted death.
Access in the United States remains limited: 11 jurisdictions (10 states plus the District of Columbia) allow assisted suicide or physician-assisted death, for patients who have a terminal diagnosis, and in some cases, only for patients who are already in hospice care. It will become legal in Delaware on Jan. 1, 2026.
In Slovenia, in 2024, 55 percent of the population who voted in a national referendum were in favor of legalizing assisted death, and parliament duly passed a law in July. But pushback from right-wing politicians then forced a new referendum, and in late November, 54 percent of those who voted rejected the legalization.
And in the United Kingdom, a bill to legalize assisted death for people with terminal illness has made its way slowly through parliament. It has faced fierce opposition from a coalition of more than 60 groups for people with disabilities, who argue they may face subtle coercion to end their lives rather than drain their families or the state of resources for their care.
Why now?
In many countries, decriminalization of assisted dying has followed the expansion of rights for personal choice in other areas, such as the removal of restrictions on same-sex marriage, abortion and sometimes drug use.
“I would expect it to be on the agenda in every liberal democracy,” said Wayne Sumner, a medical ethicist at the University of Toronto who studies the evolution of norms and regulations around assisted dying. “They’ll come to it at their own speed, but it follows with these other policies.”
The change is also being driven by a convergence of political, demographic and cultural trends.
As populations age, and access to health care improves, more people are living longer. Older populations mean more chronic disease, and more people living with compromised health. And they are thinking about death, and what they will — and won’t — be willing to tolerate in the last years of their lives.
At the same time, there is diminishing tolerance for suffering that is perceived as unnecessary.
“Until very recently, we were a society where few people lived past 60 — and now suddenly we live much longer,” said Lina Paola Lara Negrette, a psychologist who until October was the director of the Dying With Dignity Foundation in Colombia. “Now people here need to think about the system, and the services that are available, and what they will want.”
Changes in family structures and communities, particularly in rapidly urbanizing middle-income countries, mean that traditional networks of care are less strong, which shifts how people can imagine living in older age or with chronic illness, she added.
“When you had many siblings and a lot of generations under one roof, the question of care was a family thing,” she said. “That has changed. And it shapes how we think about living, and dying.”
How does assisted dying work?
Beyond the ethical dilemmas, actually carrying out legalized assisted deaths involves countless choices for countries. Spain requires a waiting period of at least 15 days between a patient’s assessments (but the average wait in practice is 75 days). In most other places, the prescribed wait is less than two weeks for patients with terminal conditions, but often longer in practice, said Katrine Del Villar, a professor of constitutional law at the Queensland University of Technology who tracks trends in assisted dying
Most countries allow patients to choose between administering the drugs themselves or having a health care provider do it. When both options are available, the overwhelming majority of people choose to have a health care provider end their life with an injection that stops their heart.
In many countries only a doctor can administer the drugs, but Canada and New Zealand permit nurse practitioners to provide medically assisted deaths too.
One Australian state prohibits medical professionals from raising the topic of assisted death. A patient must ask about it first.
Who determines eligibility is another issue. In the Netherlands, two physicians assess a patient; in Colombia, it’s a panel consisting of a medical specialist, a psychologist and a lawyer. The draft legislation in Britain would require both a panel and two independent physicians.
Switzerland and the states of Oregon and Vermont are the only jurisdictions in the world that explicitly allow people who are not residents access to assisted deaths.
Most countries permit medical professionals to conscientiously object to providing assisted deaths and allow faith-based medical institutions to refuse to participate. In Canada, individual professionals have the right to refuse, but a court challenge is underway seeking to end the ability of hospitals that are controlled by faith-based organizations and that operate with public funds to refuse to allow assisted deaths on their premises.
“Even when assisted dying has been legal and available somewhere for a long time, there can be a gap between what is legal and what is acceptable — what most physicians and patients and families feel comfortable with,” said Dr. Sisco van Veen, an ethicist and psychiatrist at Amsterdam Medical University. “And this isn’t static. It evolves over time.”
Jin Yu Young in Seoul, José Bautista in Madrid, José María León Cabrera in Quito, Veerle Schyns in Amsterdam and Koba Ryckewaert in Brussels contributed reporting.
Health
Peptides may soon be easier to get amid RFK Jr’s push, but experts warn of risks
NEWYou can now listen to Fox News articles!
The Food and Drug Administration (FDA) will reportedly weigh easing restrictions on peptides in anticipated talks.
The meeting, which is expected to be held in July, will discuss relaxing limits on more than a half dozen peptide injections.
Peptides are short chains of amino acids — the building blocks of proteins — that play key roles in biological functions, according to the National Institutes of Health. Peptide drugs are lab-made versions of natural molecules in the body that are designed to mimic or influence biological signals to treat disease, experts say.
PARALYZED MAN WALKS AGAIN AFTER EXPERIMENTAL DRUG TRIAL TRIGGERS REMARKABLE RECOVERY
In a federal notice released Wednesday, the FDA identified these drugs — used for conditions ranging from insomnia to obesity — for potential inclusion on a list of substances that can be safely compounded by pharmacies.
Human Services Secretary Robert F. Kennedy Jr. does pull-ups during a conference at Ronald Reagan Washington National Airport in Arlington, Va., on Dec. 8, 2025, discussing the launch of the “Make Travel Family Friendly Again” campaign. (Heather Diehl/Getty Images)
This follows Health and Human Services Secretary Robert F. Kennedy Jr.’s push to deregulate peptides, which he’s spoken about publicly, although most peptides have not been reviewed for safety by the FDA.
Kennedy has discussed using the substances for personal injuries. In a recent interview on “The Joe Rogan Experience” podcast, he stated that he’s a “big fan of peptides.”
ARE PEPTIDES THE FOUNTAIN OF YOUTH? DOCTORS WARN HYPE MAY OUTPACE SCIENCE
The HHS secretary mentioned that he’s “very anxious” to making some peptides “more accessible.”
“My hope is that they will get moved to a place where people have access from ethical suppliers,” Kennedy said, alluding to the FDA taking action.
What to know about peptides
Peptides have gained popularity among wellness influencers and fitness gurus as a means of building muscle, healing injuries or appearing younger, the AP reported.
CLICK HERE FOR MORE HEALTH STORIES
Peptides act like a signal to hormones and the human body. Similar to how GLP-1s (glucagon-like peptide-1 agonists), such as Ozempic, suppress appetite and trigger weight loss, peptides can signal other functions, like the release of growth hormones.
Peptides have gained popularity for outcomes like building muscle, healing injuries or appearing younger, the AP reported. (iStock)
Certain peptides up for review by the FDA, like BPC-157, are marketed for tendon healing, gut healing (in cases like ulcerative colitis), injury recovery and inflammation reduction, although the FDA has warned about the risk of unapproved peptide treatments.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The FDA wrote in a February advisory that “compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.”
“Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy,” the agency wrote.
The FDA wrote in a February advisory that “compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.” (Sarah Silbiger/Getty Images)
The current peptide market has been referred to as the “Wild West” due to lack of regulation. In an interview with AP, Dr. Peter Lurie, a former FDA official who now leads the Center for Science in the Public Interest in Washington, D.C., commented that “the Wild West is about to become wilder.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“I don’t see why one would take the path of proper drug approval if there is now this less rigorous, alternative path to market,” he said.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Under the Biden administration, the FDA added nearly 20 peptides to a list of substances that should not be produced by compounding pharmacies, according to the AP.
The panel of pharmacy advisers at the time noted that the peptides did not meet criteria for safety.
Health
This could be why your weight-loss medication isn’t delivering results
NEWYou can now listen to Fox News articles!
The skyrocketing popularity of GLP-1 receptor agonists has transformed the weight-loss industry, but not all shots are created equal in terms of how they work.
A study published in Nature investigated how genes affect the success of modern weight-loss drugs — specifically, GLP-1s like semaglutide and tirzepatide.
In analyzing genetic data and self-reported weight loss from over 27,000 users, researchers pinpointed a specific variation in the GLP-1 receptor gene (GLP1R) that acts as a “booster” for the drug’s effectiveness.
POPULAR WEIGHT-LOSS MEDICATIONS LINKED TO HIDDEN SIDE EFFECTS, STUDY FINDS
Individuals carrying one copy of this variant lost an average of 1.6 pounds more than those without it, according to the findings.
This suggests that genetic testing could eventually help doctors steer sensitive patients toward medications they are more likely to tolerate.
Individuals carrying one copy of a specific genetic variant lost an average of 1.6 pounds more than those without it. (iStock)
“We believe these reports are a step forward in meeting an unmet need for a more informed and personalized approach to weight management,” said study co-author Noura Abul-Husn, chief medical officer at the 23andMe Research Institute in California, in a press release.
While this genetic “boost” is measurable, it remains relatively modest when compared to the total average weight loss of 24 pounds observed across the study population, the researchers noted.
SHOULD YOU MICRODOSE OZEMPIC? EXPERTS ARE SPLIT ON RISKS VS BENEFITS
Beyond genetics, other factors such as age, sex and specific medications remain much stronger predictors of success.
For instance, the study found that women generally saw a higher body mass index (BMI) reduction (12.2%) compared to men (10.0%).
Traditional factors such as age, sex and specific medications remain much stronger predictors of success. (iStock)
The study may also reveal why certain patients experience stomach issues. Scientists identified a different genetic variant that was linked to increased reports of nausea and vomiting.
The presence of this side effect did not impact the drug’s effectiveness, however. Patients with variants in the GLP1R and GIPR genes lost just as much weight as those without it; they simply felt more sick during the process, the study found.
WEIGHT-LOSS MEDICATIONS COULD IMPACT SEXUAL HEALTH IN UNEXPECTED WAYS
“GLP-1 treatment decisions are complex, and having access to clinical expertise to help contextualize your genetic results alongside your full health picture is exactly the kind of guidance this report is designed to support,” said Abul-Husn.
Patients with the variant lost just as much weight as those without it; they simply felt more sick during the process, the study found. (iStock)
Dr. Peter Balazs, MD, a hormone and weight-loss specialist serving the New York and New Jersey area, was not involved in the study but reiterated the role of the genetic variants in treatment response and side effects.
CLICK HERE FOR MORE HEALTH STORIES
“Notably, there appears to be a drug-specific effect: The GIPR variant associated with these side effects is observed with tirzepatide, but not with semaglutide,” he told Fox News Digital.
Balazs said he was surprised by the extremely wide nausea risk range (5%–78%). “Additionally, the drug-specific genetic dissociation was unexpected,” he added.
Study limitations
The data relied on participants reporting their own weight, which could be subject to bias.
“The data is self-reported and not medically verified, which may affect its reliability firstly,” Balazs told Fox News Digital. “It also does not account for key treatment variables, such as titration, discontinuation or dosing schedules.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The 23andMe participant pool may not reflect a diverse, real-world population, he added.
“The study also lacks data on important clinical endpoints, such as diabetes progression, and severe adverse effects, such as gastroparesis or pancreatitis,” Balazs pointed out. “Many of its findings also have not been supported by more clinically and statistically robust studies.”
Patients with the variant lost just as much weight as those without it; they simply felt more sick during the process, the study found. (iStock)
For example, a sub-study comparing these reports to objective iPhone health data suggested that participants might over-report their progress. While users reported an 11.8% loss, electronic data in that subset showed a 5.8% loss.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
As an observational study rather than a controlled clinical trial, it could not definitively prove that the genetic variants caused the difference in weight loss, only that they are associated with it, the researchers noted.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“I think this article is interesting, raising the possibility of genetic factors, and the use of genetic testing incorporated into further decision-making when picking weight-loss medications,” Balazs said. “However, I would be careful to draw conclusions solely based on this study.”
Health
Considering Phentermine for Weight Loss? Who Should Take It Over a GLP-1
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
-
Ohio3 days ago‘Little Rascals’ star Bug Hall arrested in Ohio
-
Georgia1 week agoGeorgia House Special Runoff Election 2026 Live Results
-
Arkansas7 days agoArkansas TV meteorologist Melinda Mayo retires after nearly four decades on air
-
Austin, TX1 week agoABC Kite Fest Returns to Austin for Annual Celebration – Austin Today
-
Politics2 days agoDem fundraising giant in the hot seat as GOP lawmakers demand answers over dodged subpoena
-
Politics5 days agoTrump blasts Spanberger ahead of Virginia meetings, says state faces tax base exodus like New York, California
-
Health1 week agoWoman discovers missing nose ring traveled to her lungs, causing month-long cough
-
San Francisco, CA5 days agoPresident Trump terminates Presidio Trust